Biogen (BIIB) Operating Leases (2018 - 2026)
Biogen (BIIB) posted quarterly Operating Leases of $264.8 million for Q2 2026, down 14.83% year-over-year from $310.9 million in Q2 2025, and down 3.15% quarter-over-quarter from $273.4 million in Q1 2026.
Biogen (BIIB) Operating Leases (2018 - 2026) Analysis & Trends
Biogen's Operating Leases history runs 9 years deep, the most recent figure standing at $264.8 million for Q2 2026.
- In Q2 2026, Operating Leases fell 14.83% year-over-year to $264.8 million; the TTM figure through Jun 2026 stood at $264.8 million (down 14.83% YoY), while the FY2025 annual figure was $290.4 million, down 31.0% from the prior year.
- Operating Leases for Q2 2026 stood at $264.8 million, down from $273.4 million in the prior quarter.
- The five-year high for Operating Leases was $490.3 million in Q4 2023, with the low at $264.8 million in Q2 2026.
- The 5-year median for Operating Leases is $325.2 million (2023), against an average of $346.8 million.
- The sharpest annual moves came in 2024 and 2025: Operating Leases gained 24.31% in 2024, then slumped 31.0% in 2025.
- Biogen's Operating Leases stood at $430.2 million in 2022, then gained by 13.97% to $490.3 million in 2023, then slipped by 14.15% to $420.9 million in 2024, then plunged by 31.0% to $290.4 million in 2025, then decreased by 8.82% to $264.8 million in 2026.
- Business Quant data shows BIIB's Operating Leases at $264.8 million in Q2 2026, $273.4 million in Q1 2026, and $290.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 264.80 Mn |
| Mar 31, 2026 | 273.40 Mn |
| Dec 31, 2025 | 290.40 Mn |
| Sep 30, 2025 | 305.00 Mn |
| Jun 30, 2025 | 310.90 Mn |
| Mar 31, 2025 | 323.40 Mn |
| Dec 31, 2024 | 420.90 Mn |
| Sep 30, 2024 | 357.00 Mn |
| Jun 30, 2024 | 367.50 Mn |
| Mar 31, 2024 | 406.50 Mn |
| Dec 31, 2023 | 490.30 Mn |
| Sep 30, 2023 | 428.80 Mn |
| Jun 30, 2023 | 304.40 Mn |
| Mar 31, 2023 | 327.00 Mn |
| Dec 31, 2022 | 430.20 Mn |
| Sep 30, 2022 | 354.80 Mn |
| Jun 30, 2022 | 274.20 Mn |
| Mar 31, 2022 | 312.30 Mn |
| Dec 31, 2021 | 419.50 Mn |
| Sep 30, 2021 | 348.20 Mn |